
-
GH Research NasdaqGM:GHRS GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Location: Joshua Dawson House, Dublin, D02 RY95, Ireland | Website: https://www.ghres.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
458.6M
Cash
291.3M
Avg Qtr Burn
-10.32M
Short % of Float
14.44%
Insider Ownership
33.88%
Institutional Own.
68.88%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 2b Update | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Postpartum depression | Phase 2a Update | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Bipolar depression | Phase 2a Update | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 1 Data readout | |
GH002 (IV mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 1 Update |